Forskningshistorik
Enzymaticas forskningsresa
Ett stort antal kliniska och in vitro-studier har genomförts genom åren och stödjer de kliniska fördelarna med ColdZyme samt visar den effektiva verkningsmekanismen bakom dessa.
Steg 3Bevisa teorin: Bredare fokus på övre luftvägsinfektioner
Mätning av den skyddande effekten mot ett bredare spektrum av övre luftvägsvirus, med tester på fler än 10 luftburna virus och varianter.
Nya oberoende studier visar att ColdZyme verkar på grundorsaken till luftvägsinfektioner och minskar antalet sjukdagar och symtom
Feb. 2025
Glen Davison, University of Kent, England and Doris Wilflingseder, Ignaz Semmelweis Institute and Vetmeduni Vienna.
Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load
Sept. 2024
Glen Davison, University of Kent, England
Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
Aug. 2024
Glen Davison, University of Kent, England
Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
Jun. 2024
Glen Davison, University of Kent, England
Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat
Sept. 2023
Glen Davison, University of Kent, England
ColdZyme breaks viral infection cycle – significantly reducing influenza viral load
Aug. 2023
Doris Wilflingseder, Medical University of Innsbruck, Austria
ColdZyme® protects airway epithelia from infection with BA.4/5 | Respiratory Research | Full Text (biomedcentral.com)
Oct. 2022
Viktoria Zaderer, Stefanie Dichtl, Rosa Bellmann Weiler, Cornelia Lass Flörl, Wilfried Posch & Doris Wilflingseder
Inactivation of SARS CoV-2 and HCoV-229E in vitro by ColdZyme®
Oct. 2022
Gudmundsdottir Á, Scheving R, Lindberg F, Stefansson B
Effects of ColdZyme® Mouth Spray on upper respiratory tract infection URTI duration and viral load in endurance athletes.
May 2021
Glen Davison, University of Kent, Canterbury, UK
Steg 2Bevisa teorin – förkylning: in-vivo
Bedömning av hur mycket virusmängden minskar samt förmågan att skydda människor från orsakerna till förkylning, inklusive påverkan på symptom samt inverkan på människors livskvalitet.
Coldzyme® Mouth Spray reduces duration of upper respiratory tract infection symptoms in endurance athletes under free living conditions - Randomised to control study for a 3-months period
Jun. 2020
Glen Davison, University of Kent, Canterbury, UK
Multi-symptom Relief and Improvement of Quality of Life - A Comparative Multicenter Trial on ColdZyme® Mouth Spray in Common Cold
Apr. 2019
Fredrik Lindberg, Enzymatica AB, Lund, Sweden
Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool Staff
Nov. 2017
Mats Clarsund
Enzymatica AB, Lund, Sweden
A Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against Rhinovirus-Induced Common Cold
Nov. 2017
Mats Clarsund1, Marcus Fornbacke1, Lena Uller2, Sebastian L. Johnston3, Cecilia Ahlström Emanuelsson4
1Enzymatica AB, Lund, Sweden
2Unit of Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, Lund, Sweden
3Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, London, UK
4Department of Otorhinolaryngology, Skåne University Hospital, Lund, Sweden
Evaluation of ColdZyme Mouthspray against common cold in elderly care personnel
Feb. 2017
Mats Clarsund, Christina Bråkenhielm Persson
Steg 1Utforska enzym – in-vitro
Utvärdering av barriärskydd och dess uppmätta effekt i sårbara grupper med stort behov, inklusive effekten mot de vanligaste virusen som orsakar förkylning.
A medical device forming a protective barrier that deactivates four major common cold viruses
Nov. 2017
Bjarki Stefanson, Augusta Gudmundsdottir, A. Clarsund